Detalhe da pesquisa
1.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood
; 2024 Mar 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38551807
2.
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
Cancer
; 2024 May 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38804723
3.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38591430
4.
Impact of ABO and Rhesus blood groups on COVID-19 susceptibility and severity: A case-control study.
J Med Virol
; 94(3): 1162-1166, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34755349
5.
Central Nervous System Prophylaxis and Treatment in Acute Leukemias.
Curr Treat Options Oncol
; 23(12): 1829-1844, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36510037
6.
Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Am J Hematol
; 99(7): 1423-1426, 2024 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-38607091
7.
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk
; 24(4): e168-e173, 2024 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38212207
8.
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Blood Adv
; 8(4): 909-915, 2024 Feb 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38207208
9.
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
J Clin Oncol
; 42(13): 1499-1508, 2024 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38277619
10.
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience.
Cancers (Basel)
; 16(9)2024 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38730715
11.
Liquid biopsies and minimal residual disease in lymphoid malignancies.
Front Oncol
; 13: 1173701, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37228488
12.
Systemic AL amyloidosis: current approach and future direction.
Oncotarget
; 14: 384-394, 2023 04 26.
Artigo
Inglês
| MEDLINE | ID: mdl-37185672
13.
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
J Hematol Oncol
; 16(1): 73, 2023 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37422688
14.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
medRxiv
; 2023 Dec 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38106221
15.
Adhesion molecules in multiple myeloma oncogenesis and targeted therapy.
Int J Hematol Oncol
; 11(2): IJH39, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35663420
16.
A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology.
Cancers (Basel)
; 14(15)2022 Jul 28.
Artigo
Inglês
| MEDLINE | ID: mdl-35954328
17.
Lebanese Real-World Experience in Treating Multiple Myeloma: A Multicenter Retrospective Study.
Leuk Res Rep
; 15: 100252, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34141564
18.
Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports.
Case Rep Oncol
; 12(2): 421-425, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31244645
19.
AI-based online chat and the future of oncology care: a promising technology or a solution in search of a problem?
Front Oncol
; 13: 1176617, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37305580
20.
Addendum: Systemic AL amyloidosis: current approach and future direction.
Oncotarget
; 14: 721, 2023 Jul 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37477528